Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of ANS02 in EGFR-mutant advanced or metastatic non-small cell lung cancer
CTR20262448Phase 2Active
- Sponsor
- Avistone Biotechnology Co., Ltd.
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ANS02 in non-small cell lung cancer (NSCLC), sponsored by Avistone Biotechnology Co., Ltd.. Started Jul 2026; status: active.
02
Drugs
ANS02
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20262448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262448.